Six things to know about pigmentation treatment
Structured for search, voice, and AI overview extraction. These are the most frequently asked questions about pigmentation — answered clearly before the full medical education begins.
When to see a dermatologist for pigmentation
Most patients have tried two or three things before booking — over-the-counter brightening serums, social-media routines, friend recommendations, sometimes a chemist-counter mixed cream. The reason none of those produced durable improvement is usually that the pigmentation was never typed correctly. The consultation begins with diagnosis, not a product recommendation.
Book a consultation when
- Pigmentation has not improved after 8–12 weeks of a consistent OTC routine
- Patches are spreading, darkening, or recurring after temporary fading
- You are not sure whether you have melasma, post-inflammatory marks, or sun damage
- You are pregnant, post-partum, or recently changed hormonal medication
- You have used a brightening cream of unknown composition (especially mixed creams from chemists or online sellers)
- You have tried whitening / fairness products without medical guidance
Seek prompt review when
- A pigmented patch is changing rapidly in shape, size, or colour
- A mole is darkening, growing, or developing irregular edges
- Pigmentation is associated with itching, burning, or peeling
- Pigmentation appeared after starting a new medication
- Skin in the affected area appears thinned, fragile, or has visible blood vessels
Pigmentation types — and why they need different pathways
"Pigmentation" is a general term that covers several distinct conditions with different causes, prognoses, and treatments. Selecting the right pathway requires knowing which type you have. Most patients have a mix; treatment is sequenced accordingly.
Melasma
Symmetric brown or grey-brown patches on the cheeks, forehead, upper lip, and chin. Often hormonally driven, sun-sensitive, and recurrent. More common in women, particularly during and after pregnancy or with hormonal medication. Can also occur in men. Needs cautious treatment — aggressive intervention can rebound or produce patchy de-pigmentation.
Post-inflammatory hyperpigmentation (PIH)
Flat brown, grey, or violet marks left behind after inflammation — eczema, friction, an insect bite, contact dermatitis, or a procedure. Particularly common and persistent in Indian skin because the melanocyte response to inflammation is more pronounced than in lighter skin types. Each individual mark settles over weeks to months with sun protection and topicals.
Solar lentigines and photoageing
Brown patches and freckle-like spots from cumulative sun exposure, typically appearing on the face, hands, and upper chest from the late thirties onwards. Often co-exist with fine lines and uneven texture. Respond well to combined topical and selectively procedural care.
Freckles (ephelides)
Small flat tan or brown spots that appear or darken with sun exposure, typically on the face and arms, and that lighten in the absence of sun. Often present from childhood in fair-skinned individuals. Treatment is largely about sun protection; lasers can lighten but tend to be temporary without continued sun avoidance.
Tanning and sun-induced diffuse darkening
An overall darkening of sun-exposed skin from cumulative or recent intense UV exposure. Different from defined patches — more uniform, often improves significantly over months with consistent sun protection alone, sometimes assisted by topical antioxidants and gentle exfoliation under dermatologist guidance.
Drug- or hormone-induced pigmentation
Some medications (certain antibiotics, antimalarials, NSAIDs, anti-epileptics, chemotherapy agents) and hormonal events (pregnancy, OCPs, thyroid changes) can trigger or worsen pigmentation. The pattern usually points to the cause and resolves slowly after the trigger is identified and modified where possible.
Periorbital and lip darkening
Darkening around the eyes and lips. Multiple causes — genetics, friction, sun, allergic contact, vascular pooling, iron deficiency. Diagnosis requires careful examination because the right treatment differs substantially by underlying cause; a single "dark circle cream" rarely matches all of them.
Friction and pressure pigmentation
Darkening at sites of repeated rubbing — neck, underarms, inner thighs, knuckles, elbows, bra-line. Often misdiagnosed as a primary pigmentation disease. Identifying and reducing the friction source is the first step; topicals and procedures support but do not replace this.
Why the distinction matters
The topical and procedural approach for melasma is different from PIH, which is different again from solar lentigines or drug-induced patterns. A single "pigmentation cream" rarely matches more than one type well, and an aggressive single device used across all of them often makes melasma worse.
Melasma — clinical patterns, drivers, and what makes it different
Melasma is the single most common reason adults seek pigmentation care in Indian dermatology, and the most common reason patients arrive with a long list of failed products. It behaves differently from every other pigmentation pattern — chronic, recurring, sun and hormone driven, and uniquely vulnerable to over-aggressive treatment. The detail below is what we discuss with every melasma patient at consultation.
Patterns of distribution
Centrofacial — forehead, cheeks, upper lip, nose, chin. The most common pattern. Malar — limited to the cheeks and over the cheekbones; often the most visible socially. Mandibular — along the jawline and lateral lower face; sometimes confused with friction or post-inflammatory pigmentation. Distribution is usually symmetric; pattern guides the location-specific intensity of topicals and procedural support.
Epidermal versus dermal versus mixed
Epidermal melasma sits in the upper skin layer — Wood's lamp typically accentuates the contrast — and responds well to topicals and superficial peels. Dermal melasma sits deeper; Wood's lamp does not accentuate, response is slower, and lasers can worsen it if mis-calibrated. Mixed melasma — the most common pattern in established cases — has both layers and needs layered care. Depth assessment shapes how aggressively the plan moves.
Hormonal drivers
Estrogen and progesterone fluctuation activates melanocytes in genetically predisposed skin. Pregnancy is a classic precipitant; oral contraceptives and hormonal IUDs are common ongoing drivers; perimenopause re-activates melasma in patients whose pigmentation was previously controlled. Thyroid disorders contribute in a subset. Hormonal context shapes treatment timing — pregnancy pauses most actives, and hormonal medication changes are coordinated with the prescriber when relevant.
Vascular component
Melasma patches show increased dermal blood vessel density on histology. Some of the apparent "darkness" is the contribution of dilated vessels seen through pigmented skin. This is why oral tranexamic acid — which modulates vascular and inflammatory contributors — helps in resistant cases, and why heat exposure (which dilates vessels further) reliably worsens melasma flares even when sun is controlled.
The visible-light contribution
Beyond UVA and UVB, high-energy visible light contributes to melasma in Indian skin in a way that is rarely discussed in lighter-skin protocols. Tinted mineral sunscreen with iron oxides is the practical answer — the iron oxides absorb visible light, which standard chemical sunscreens do not. For a patient whose melasma keeps flaring despite "good sunscreen", switching to tinted mineral is often the single highest-value change.
Why aggressive treatment can backfire
Melasma rebounds when stimulated. Aggressive lasers, high-strength peels, and over-concentrated topicals trigger inflammation, which activates melanocytes, which re-pigments the area — sometimes worse than baseline. The careful, layered, sustained approach is not gentler because it is timid; it is gentler because biology punishes intensity in this specific condition.
Triggers most patients miss
Outside the obvious (sun, hormones), the triggers patients commonly underestimate include: kitchen heat in cooks and home cooks, hot showers and sauna habits, hot yoga, warm-weather travel, irritating actives layered too aggressively, certain photo-reactive perfumes and essential oils, and chronic friction from skincare tools. Trigger audit at consultation often reveals 2–3 modifiable contributors that no past plan addressed.
What "managed melasma" looks like
The realistic clinical goal is durable lightening, fewer and milder flares, and longer relapse-free intervals. Most patients reach a stable state where melasma is barely visible at conversational distance under most lighting, with periodic minor flares around hormonal events or sun-heavy travel. Maintenance is permanent. "Cured" is the wrong frame; "controlled" is the right one.
Post-inflammatory hyperpigmentation — patterns and pathway
PIH is one of the most common and one of the most under-addressed pigmentation patterns in Indian skin. Unlike melasma, it usually has an identifiable inflammatory event behind each mark. Once the upstream inflammation is settled and the right topical layer is in place, most cases improve on a predictable timeline — which is reassuring news for patients who have been told their dark marks are permanent.
How PIH actually forms
Inflammatory mediators released during eczema, contact dermatitis, friction, insect bites, acne lesions, or any procedure trigger melanocyte activation in surrounding skin. Pigment is then transferred to keratinocytes and rises through the epidermis. In Indian skin, the response is more pronounced and longer-lasting than in lighter skin. Each individual mark is a small contained event with its own timeline.
Epidermal versus dermal PIH
Most PIH is predominantly epidermal — brown, sharply demarcated, responsive to topicals and time. Long-standing or repeatedly traumatised PIH can drop pigment into the dermis, becoming grey-violet, more diffuse, and slower to clear. Dermoscopy and history together suggest depth; the plan respects what depth implies for timeline.
Treating the upstream cause first
Pigment-modulating topicals applied to skin that is still inflaming will not deliver durable improvement — fresh inflammation re-fills the pigment tank as fast as topicals empty it. The first step in any PIH plan is identifying and settling the upstream cause: acne, eczema, friction, contact reaction, picking. Once the upstream is stable, the pigment side responds.
Realistic timeline for PIH
Recent epidermal PIH (under 6 months old) typically improves substantially in 8–12 weeks of consistent topical use plus daily sun protection. Older or dermal-component PIH (12+ months) often needs 4–6 months of layered care, sometimes with selected superficial peels. Each individual mark has its own timeline; the average is reassuring but individual marks vary.
PIH versus PIE — different pathway
Post-inflammatory erythema (PIE) is flat red or pink, vascular, and follows the same inflammatory events but without melanocyte involvement. PIE is more common in lighter skin and may co-exist with PIH in Indian skin. PIE responds to time, sun protection, and selected vascular lasers if persistent — not to tyrosinase inhibitors. Confusing them wastes months of topical treatment on the wrong target.
Preventing the next round of PIH
For acne-prone patients, controlling the underlying acne is the single largest PIH-prevention step. For eczema or contact dermatitis, identifying and avoiding triggers is the rate-limiting factor. For friction-zone PIH, addressing the friction source matters more than any cream. The plan addresses upstream prevention alongside downstream pigment reduction so the next inflammatory event does not re-fill the same pattern.
Tanning and diffuse sun-induced darkening — the pathway most people DIY
Many patients who book pigmentation consultation actually have diffuse sun-induced darkening rather than a defined pigmentation disease. This is good news — the largest gains here usually come from sun habits, not aggressive procedures. Understanding the difference protects you from over-treatment.
How tanning actually behaves
Tanning is the protective melanin response to UV exposure — adaptive, reversible, and present in everyone with melanocytes. In Indian skin it is more pronounced than in lighter skin and lingers longer once the exposure stops. Diffuse darkening of the face, neck, V of chest, and dorsa of hands without defined patches is usually tanning, not melasma or lentigines.
Why most of the improvement is biological
If the UV stimulus is reduced, melanocyte activity drops and existing pigmented keratinocytes shed naturally over the epidermal turnover cycle (roughly 4 weeks at any given site). Within 3–6 months of consistent sun protection, diffuse tan typically lightens significantly without any procedure at all. Over-treating tanning with aggressive lasers or peels in Indian skin is a common cause of paradoxical worsening.
What does help — when used carefully
Daily SPF 50 PA+++ broad-spectrum sunscreen (the most important step). Antioxidant serum during the day, particularly relevant in Delhi pollution conditions. Topical retinoid at night to accelerate epidermal turnover. Selected gentle exfoliating peels at 4-week intervals. Niacinamide as a supportive layer. None of these are aggressive, and the cumulative effect over months is significant.
What does not help — and often hurts
"Whitening" creams of unknown composition, especially those containing undisclosed steroids. Aggressive Q-switched laser protocols designed for solar lentigines applied across diffusely tanned skin. Weekly aggressive peels. Home-mixed lemon, turmeric, and other photo-reactive irritants. All of these commonly worsen pigmentation in Indian skin through inflammation, rebound, or paradoxical response.
Tan lines and asymmetric tanning
Patients sometimes present with sharp pigmentation contrasts — between the part of the face exposed during commute and the covered part, or between hands that drive a vehicle and hands that do not. The driver-side pigmentation pattern is recognisable and addressed through window film, gloves, and structural sun protection alongside topicals.
Travel and seasonal tanning
A beach holiday, mountain trek, or high-altitude trip can re-darken even well-managed skin in a few days. The plan around travel is preventive — high SPF, frequent reapplication, protective clothing, hat, and sunglasses — not corrective afterwards. Patients planning travel within a pigmentation course should disclose dates so the dermatologist sequences sessions sensibly around them.
Hormonal, drug-induced, and friction pigmentation — find the cause first
A subset of pigmentation patterns trace cleanly back to a specific upstream cause — a medication, a hormonal event, a friction source. In these cases, the topical and procedural plan matters less than identifying and addressing the cause. Treatment without that step plateaus or reverses.
Hormonal pigmentation beyond classic melasma
Beyond standard melasma patterns, hormonal pigmentation can show up as diffuse darkening around the eyes during pregnancy, friction-pattern darkening in the inner thighs and underarms with hormonal medication, and re-flare of long-quiet melasma at perimenopause. The plan reflects the hormonal context — pause where pregnancy or breastfeeding requires, coordinate with prescribers where medication changes are reasonable, and time aggressive work to stable hormonal phases.
Drug-induced pigmentation patterns
Common offenders include minocycline (slate-grey patches on face, lower legs, scars), hydroxychloroquine (dusky discolouration of palate, shins, nail beds), certain anti-epileptics (diffuse darkening), tetracyclines (photo-aggravated patterns), and selected chemotherapy agents (specific drug-related patterns). Onset coincides with the medication; resolution after stopping is slow. The plan is identification, prescriber discussion, and patient sun protection while the pigment fades over months.
Friction and pressure pigmentation
The neck, underarms, inner thighs, knuckles, elbows, and bra-line are the classic sites. Repeated rubbing from clothing, jewellery, waxing, threading, and aggressive scrubbing produces low-grade chronic inflammation that triggers pigment in already-reactive Indian skin. Identifying the friction source — and reducing it — is the single largest lever. Topicals and selected procedural support help, but without the friction reduction, response plateaus.
Photo-contact pigmentation
Some perfumes, essential oils, and herbal extracts contain photo-reactive compounds (psoralens, certain citrus oils, fig sap). When these are applied to skin and the skin then sees sun, a sharply demarcated pigmented streak can appear — often along the line where perfume was sprayed or oil applied. Identifying the offender is the entire treatment; pigment fades over months once the trigger is removed and sun protection is consistent.
Pigmentation in chronic medical conditions
Thyroid disorders, severe iron deficiency, vitamin B12 deficiency, and a few endocrine conditions can manifest as periorbital and diffuse pigmentation. Investigation is selective — not every patient needs blood tests, but where the history or examination suggests a contributor, targeted investigations are recommended. Correcting the deficiency is the right starting point; the pigment itself fades over months once the upstream is addressed.
Cosmetic-product reactions
Some cosmetic products — particularly mixed creams of unknown composition and certain "skin lightening" formulations — produce specific pigmentation patterns through chronic irritation, photoreactivity, or exogenous ochronosis. These look unlike standard pigmentation patterns and require specific management — discontinuation of the offender, supportive barrier care, and patience for the slow fade. They are also prevention's strongest argument for staying away from undisclosed combinations.
Type-by-type field guide — how each pattern actually presents
Most patients arrive with a single working label — usually "melasma" or "dark spots" — that does not match what is actually on their skin. The features below describe how each pigmentation pattern typically presents, where it sits on the face or body, and the cues the dermatologist looks for at the consultation. None of these are diagnostic on their own; the pattern is what counts.
Melasma — the typical presentation
Symmetric, ill-defined patches with a reticulated or "lace-like" inner edge. Most often on the cheeks (malar pattern), forehead and temples, upper lip and chin (centrofacial pattern), or along the jawline (mandibular pattern). Colour ranges from light brown in early epidermal melasma to grey-brown in mixed or dermal-component cases. Worsens with sun and heat exposure; lightens incompletely between flares. Symmetry is the strongest visual clue — asymmetric facial pigmentation is rarely classic melasma.
PIH — the typical presentation
Discrete flat marks that match the footprint of an earlier inflammatory event — old acne lesions, eczema patches, scratch lines, friction marks, insect bites. Colour varies: brown in epidermal PIH, grey-violet in deeper or chronic PIH. Distribution is asymmetric and "story-driven" — patients can usually point to what was there before. Marks do not appear on skin that has not had a prior event.
Solar lentigines — the typical presentation
Discrete brown patches and freckle-like spots, typically 2–10 mm across, on photo-exposed sites — face, dorsa of hands, upper chest, shins. Onset usually from late thirties onwards. Colour is uniform within each spot, edges are sharper than melasma, and lesions are stable rather than cyclically darkening. Often co-exist with fine lines and uneven texture in surrounding photoageing.
Freckles (ephelides) — the typical presentation
Small flat 1–3 mm tan or light brown spots, present from childhood, that darken in summer and lighten in winter. Most common on the nose, cheeks, and arms in lighter Fitzpatrick types. The seasonal dependence is a useful cue — freckles change month-to-month, while solar lentigines remain stable through the year.
Tanning and diffuse sun darkening — the typical presentation
Uniform darkening of photo-exposed skin without defined patches — usually the face, neck, V of the chest, and dorsa of hands. Often a sharp contrast at the line where shorts or sleeves meet covered skin. Colour is usually warmer (golden to deep tan), distinct from the cool grey-brown of dermal melasma. Improves significantly over months with sun avoidance even before any topical work begins.
Periorbital pigmentation — the typical presentation
Darkening around the eyes that may be brown (true pigment), violet-blue (vascular pooling under thin skin), or shadowed (structural — tear-trough hollow). Often a mix. The pinch test, the lying-down test, and side-lighting at consultation help separate components. A single "dark circle cream" rarely matches the actual underlying cause.
Friction-zone pigmentation — the typical presentation
Brown to grey-brown darkening at sites of repeated rubbing — neck, underarms, groin, inner thighs, knuckles, elbows, bra-line. Often misdiagnosed as "acanthosis nigricans" or "primary pigmentation". Texture is often slightly thickened in chronic cases. The cue is the pattern matches a friction source — clothing seam, jewellery, repeated waxing, scrubbing.
Drug-induced pigmentation — the typical presentation
Onset coincides with a new medication. Colour often grey-blue, slate, or dusky brown rather than the warm tan of sun-driven patterns. Distribution may follow photo-exposed sites (photo-aggravated) or be diffuse. Common offenders: minocycline (slate-grey patches), antimalarials (dusky pigmentation of palate, shins, nail beds), certain chemotherapy agents. The history is the key; pattern alone is rarely diagnostic.
Why "looks like melasma" is often not melasma
A common pattern at consultation is a patient who has used "melasma cream" for months without improvement — and on examination, the pigmentation is actually PIH from chronic friction, photo-distributed lentigines, or drug-induced. Melasma-specific treatment does not match these patterns. Typing changes the plan, and the plan changes the result.
Causes and triggers
Pigmentation is the result of melanocytes producing more melanin than usual, distributed unevenly across the skin. Several triggers — often combined — drive that response. Identifying which triggers are active in your case is part of the consultation.
Ultraviolet and visible light
UVA, UVB, and high-energy visible light all stimulate melanocyte activity. Indian latitudes, indoor exposure near windows, and screen-emitted visible light all contribute. Sun is the most modifiable trigger and the foundation of any pigmentation plan.
Hormonal influence
Estrogen and progesterone fluctuation — pregnancy, OCPs, hormonal IUDs, perimenopause — drive melasma. Thyroid disorders and PCOS can also influence pigmentation. Hormonal context shapes the plan; investigations are recommended where the history points that way.
Inflammation
Eczema, contact dermatitis, friction, insect bites, and any procedure that breaches the skin can trigger PIH in Indian skin. The inflammatory event need not be severe — even mild persistent irritation can leave marks that take months to settle.
Heat exposure
Repeated heat — kitchen work, hot showers, certain spas and saunas — can trigger or worsen melasma independent of UV. Heat protection (cooling skin, avoiding direct heat sources) is part of melasma management even when sunscreen is in place.
Medications
Certain antibiotics (tetracyclines, minocycline), antimalarials (hydroxychloroquine, chloroquine), NSAIDs, anti-epileptics, and chemotherapy agents can cause drug-induced pigmentation. The pattern usually points to the cause and resolves slowly after the drug is stopped or substituted in consultation with the prescriber.
Cosmetic and ingredient reactions
Photoreactive fragrance, certain plant extracts (psoralens), and irritant ingredients can trigger contact pigmentation. Whitening / fairness products of unknown composition — particularly mixed creams from chemists or online sellers — frequently contain undisclosed steroids and high-strength tyrosinase inhibitors that produce thinning, telangiectasia, and rebound pigmentation.
Friction and pressure
Repeated rubbing from waxbands, tight straps, jewellery clasps, or aggressive scrubbing produces friction-related darkening that is often mistaken for a "pigmentation disease". The first step is identifying and reducing the friction source.
Pollution and oxidative stress
Particulate pollution (PM2.5, PM10) and ozone create oxidative stress that amplifies pigment formation in already-reactive skin. Antioxidant serums plus daily cleansing help reduce the oxidative load — particularly relevant in Delhi winter air-quality conditions.
Iron and vitamin deficiencies
Severe iron deficiency, vitamin B12 deficiency, and certain endocrine conditions can manifest as periorbital and diffuse pigmentation. Investigation is selective, guided by history. Correcting the deficiency does not remove pigment instantly but stops the upstream driver.
Risk factors
These factors do not predict pigmentation, but they raise the probability and shape the treatment plan. Most are constitutional; a few are modifiable.
Fitzpatrick III–V skin
Indian skin has higher baseline melanin and more reactive melanocytes. Both make pigmentation more likely after any inflammatory or sun event and more persistent once formed. The plan reflects this from the first step — gentler procedures, longer intervals, more emphasis on prevention.
Female sex and reproductive age
Hormonal pigmentation, especially melasma, is substantially more common in women between 20 and 50. Pregnancy and OCP use are common precipitants. Men can develop melasma too — the proportion is smaller but the pattern is similar.
Family history of melasma
A genetic predisposition runs in families. If a parent or sibling has melasma, your risk is higher and management may need to be more sustained — both during the active phase and through long-term maintenance.
Outdoor occupation or commute
Prolonged outdoor exposure raises cumulative UV dose and pushes pigmentation. Patients with significant outdoor time need higher-frequency sunscreen reapplication, protective clothing, wide-brim hats, and where relevant, window film for vehicles.
Recent inflammatory skin disease
Active or recent eczema, contact dermatitis, or any inflammatory rash sets the stage for PIH. Treating the underlying inflammation is part of the pigmentation plan, not separate from it.
History of steroid-cream or mixed-cream use
Long-term use of topical steroids — including over-the-counter mixed creams sold for "fairness" — can produce thinning, telangiectasia, rebound pigmentation, and steroid-induced rosacea. This history changes the safe starting point of treatment and often requires a careful weaning phase before primary pigmentation work can begin.
Hot occupational environments
Cooks, bakers, and patients who work near furnaces or in hot kitchens have repeated heat exposure that can drive melasma independent of UV. Heat protection (face shields, cooling, breaks away from heat) is part of management.
Photosensitising medications
Tetracyclines, certain antifungals, NSAIDs, and other photosensitisers raise pigmentation risk during sun exposure. Disclose all medication at consultation; the dermatologist may co-ordinate with your prescriber if a substitution is reasonable.
High-glycaemic diet and metabolic factors
Insulin resistance can amplify androgen-driven pigmentation pathways in some patients. Diet is a supportive lever, not a primary treatment, but where insulin resistance or PCOS is present, addressing it improves overall response.
Melanocyte biology — why over-pigmentation happens
Understanding the basic mechanism helps explain why the treatment plan is layered and why no single product solves the problem. Pigmentation is the visible result of an upstream chain — and most effective treatments interrupt the chain at multiple points rather than just trying to bleach the surface.
The melanocyte and the keratinocyte
Melanin is produced by melanocytes in the basal layer of the epidermis. Each melanocyte hands off pigment to surrounding keratinocytes through tiny finger-like projections (dendrites). The pigment then rises with the keratinocytes as they differentiate towards the surface. Treatment can interrupt this at three points: production, transfer, or turnover.
Tyrosinase — the rate-limiting enzyme
Tyrosinase is the enzyme that initiates melanin production. Many topical agents — hydroquinone, kojic acid, azelaic acid, arbutin, tranexamic acid — work by inhibiting or modulating tyrosinase. Combination is more effective than any single agent at the same concentration.
Triggers that activate melanocytes
UV radiation, visible light, inflammatory cytokines, hormonal signals, friction, and heat all activate melanocytes. This is why every pigmentation plan starts with sun protection and trigger control — without addressing upstream activation, downstream agents fight a constantly refilled tank.
Epidermal vs dermal pigment
Pigment that sits in the epidermis (upper skin layer) is more responsive to topical treatment and improves faster. Pigment that has dropped into the dermis (deeper layer) — sometimes seen in long-standing melasma or after repeated picking — is harder to clear and needs longer treatment with cautious procedural support. Wood's lamp and dermoscopy help distinguish.
Inflammation amplifies everything
Any inflammatory event — even mild irritation from the wrong product — releases mediators that activate melanocytes and worsen existing pigmentation. This is why "more is more" approaches (high-strength acids, mixed creams, aggressive lasers) often produce paradoxical worsening in Indian skin.
Vascular component
Melasma in particular has a vascular component — increased blood vessel density in affected patches contributes to the darker appearance. This is why some patients respond to vascular-targeted treatments and why oral tranexamic acid (which reduces vascular contribution) helps in resistant melasma.
How pigment is actually made — and where treatments interrupt the chain
Pigmentation is the visible result of an upstream chain — production, transfer, turnover. Effective treatments interrupt the chain at multiple points rather than just trying to bleach the surface. The diagram below maps the chain and shows which agents act where.
Where the pigment sits — and why depth changes the plan
Pigment depth determines treatment intensity and timeline. Wood's lamp examination and dermoscopy together with history give the dermatologist a depth estimate that guides the plan. The visual below summarises what each depth pattern looks like under examination and what it means for treatment.
Assessment before treatment
Treatment selection depends on knowing the exact type, depth, distribution, hormonal context, and prior treatment history. The first consultation is where this assessment happens — not at a treatment booking. Each step below produces specific data that drives the plan.
Visual examination and dermoscopy
Side-lighting, dermoscopic magnification, and standardised photographs reveal pigmentation features that are difficult to see in normal mirror viewing. The pattern often points strongly to the type — symmetric facial patches, friction-zone darkening, photo-distributed lentigines, isolated marks at sites of past inflammation.
Wood's lamp examination
A long-wavelength ultraviolet lamp used selectively to help differentiate epidermal from dermal pigmentation. Epidermal pigmentation is typically more responsive to topical therapy; dermal or mixed pigmentation needs longer treatment and more cautious procedural choices. Not used in every case — selected when the visual examination alone is not conclusive.
History review
Hormonal status, pregnancy and OCP history, recent medications, occupational sun exposure, prior treatments, current home routine, and any history of mixed-cream or whitening-product use — all reviewed before any procedural plan is built. Mixed-cream history particularly changes the safe starting point.
Investigations where indicated
Selected cases benefit from blood investigations — thyroid panel, hormone profile, ferritin, vitamin B12, vitamin D — when the history suggests an underlying contributor. These are not routine but are recommended when the clinical picture warrants them.
Photographic documentation
Standardised baseline photographs in fixed light, distance, and angle are taken for objective comparison at follow-up visits. Patient self-impression in a phone mirror tends to underestimate gradual change; the photographs settle the question.
Differential diagnosis
Selected pigmented conditions look like melasma but are not — Hori's macules (acquired bilateral nevus of Ota-like macules), lichen planus pigmentosus, exogenous ochronosis from chronic hydroquinone misuse, drug-induced patterns. The dermatologist screens for these because they need different pathways.
Epidermal vs dermal vs mixed pigmentation
Pigmentation depth determines how it is treated and how quickly it responds. Wood's lamp examination at consultation helps differentiate; in some cases dermoscopy and the history pattern are enough to guide the plan.
Epidermal
Pigment sits in the upper layer of the skin. Wood's lamp examination usually accentuates the contrast. These patterns respond best to topicals — tyrosinase inhibitors, retinoids, and selected superficial peels — over 8–12 weeks. Early PIH and many mild melasma patterns are predominantly epidermal.
Mixed
Pigment is present in both epidermis and dermis. Wood's lamp shows partial accentuation. Most established melasma falls in this category. Treatment combines topical and supportive procedural work; oral tranexamic acid is added selectively. Realistic timeline is 4–6 months for substantial change, with continued maintenance afterwards.
Dermal
Pigment sits primarily in the dermis. Wood's lamp does not accentuate the contrast much. Topical response is slower. Plans are longer (6–12 months for visible change), and cautious low-fluence Q-switched Nd:YAG laser may be considered as an adjunct after baseline topicals. Aggressive lasers worsen these patterns and are explicitly avoided.
Why depth matters for sequencing
Starting an aggressive procedure on dermal pigmentation is one of the most common reasons melasma worsens after "treatment". The right sequence is: depth assessment first → topicals + sun protection foundation → cautious procedural adjuncts only if needed. The plan respects the biology, not the patient's preferred timeline.
Treatment options matched to pigmentation type
Pigmentation treatment is layered. Sun protection is universal. Topicals are the foundation for most cases. Peels and selective laser toning are added selectively. Aggressive lasers are rarely the right first step in Indian skin, and never the right first step for melasma.
Foundation — universal for every type
- SPF 50 PA+++ broad-spectrum sunscreen daily, reapplied every 3–4 hours outdoors
- Tinted mineral sunscreen with iron oxides for melasma — adds visible-light protection
- Wide-brim hat and sunglasses for outdoor exposure
- Window-side and indoor exposure still requires sunscreen — UVA passes through glass
- Trigger control — heat, friction, identified ingredient or drug exposures
For melasma
- Topical tyrosinase inhibitors — supervised hydroquinone short-term, kojic acid, azelaic acid, arbutin
- Topical retinoid — accelerates epidermal turnover; introduced gradually to limit irritation
- Niacinamide — supportive ingredient that limits pigment transfer
- Selected superficial peels — glycolic, mandelic, lactic, kojic at calibrated concentrations
- Oral tranexamic acid — selectively, for resistant cases, after risk assessment
- Low-fluence Q-switched Nd:YAG (laser toning) — adjunct only, by experienced operator, with caution
For post-inflammatory hyperpigmentation
- Treat the underlying inflammation first — eczema, dermatitis, friction
- Tyrosinase inhibitor + retinoid for 8–12 weeks under supervision
- Niacinamide as a supportive ingredient
- Mandelic or glycolic peels — calibrated, 3–4 weeks apart
- Most cases improve substantially with topicals and time alone
For solar lentigines and photoageing
- Topical retinoid + tyrosinase inhibitor as foundation
- Selective Q-switched laser for individual lentigines (different parameters from melasma toning)
- Glycolic or low-strength TCA peels for diffuse photoageing
- Antioxidant serums — vitamin C as supportive layer
For tanning and sun-induced darkening
- Strict sun protection — most of the improvement comes from this
- Vitamin C and other antioxidants for daily use
- Gentle exfoliating routine under dermatologist guidance
- Time — most diffuse tanning lightens significantly over 3–6 months of consistent sun avoidance
For drug- or ingredient-induced pigmentation
- Identify and discontinue or substitute the trigger where possible (in consultation with the prescriber)
- Sun protection becomes critical to allow gradual fade
- Topical brightening as supportive care
- Patience — these patterns often improve over many months once the trigger is removed
Treatment sequencing by pigmentation type
Knowing the type is half the work; the order in which you do things is the other half. The sequences below describe how a typical plan unfolds over weeks and months for each pigmentation pattern. Real plans flex based on response at each review point.
Sequence for melasma
- Weeks 1–4 – Sunscreen audit, tinted mineral SPF 50 PA+++ established, trigger control reviewed, pigment-modulating topicals introduced gradually.
- Weeks 4–12 – Combination topicals at calibrated concentrations; first review at week 8 for tolerance; first superficial peel introduced if indicated.
- Months 3–6 – Adjustments to topical layer based on response; oral tranexamic acid considered for resistant cases after risk assessment; selected low-fluence Q-switched Nd:YAG only if topicals have plateaued.
- Months 6–12 – Maintenance phase begins; continued sun protection, periodic topical cycles, annual review.
- Long-term – Permanent sun protection, periodic topical cycles around hormonal events or sun-heavy seasons, annual photographic comparison.
Sequence for PIH
- Weeks 1–2 – Identify and treat the upstream cause — acne, eczema, friction, or other inflammatory event.
- Weeks 2–6 – Tyrosinase inhibitor + retinoid layer introduced; sunscreen reinforced; barrier-supporting routine in place.
- Weeks 6–12 – First mid-plan review with photographs; selected superficial peel (mandelic, glycolic, lactic) if indicated; topical concentrations adjusted.
- Months 3–6 – Continued layered topicals; most early epidermal PIH improves substantially in this window.
- Long-term – Maintenance sunscreen and periodic topical cycles around any future inflammatory events; rapid re-engagement if new PIH appears.
Sequence for solar lentigines and photoageing
- Weeks 1–4 – Sunscreen and antioxidant layer established; topical retinoid + tyrosinase inhibitor introduced gradually.
- Months 1–3 – Selective Q-switched laser sessions for individual lentigines (different parameters from melasma toning); glycolic or low-strength TCA peels for diffuse photoageing.
- Months 3–6 – Refinement passes for any persistent lentigines; continued topical layer.
- Long-term – Daily sun protection, antioxidant serum, and periodic review; new lentigines treated promptly as they appear.
Sequence for tanning and diffuse darkening
- Weeks 1–2 – Strict sun protection routine established; antioxidant layer added; sun habits audited.
- Weeks 2–8 – Topical retinoid at night; gentle exfoliating routine under guidance; vitamin C in the morning.
- Months 2–4 – Selective superficial peels (mandelic, glycolic) at 4-week intervals if indicated.
- Months 3–6 – Most diffuse tan lightens significantly through this window with minimal procedural intervention.
- Long-term – Sun protection becomes the maintenance plan; lasers are not the right tool for diffuse tanning.
Sequence for friction-zone pigmentation
- Weeks 1–2 – Identify friction source — clothing seam, jewellery, hair-removal habit, scrubbing — and reduce it.
- Weeks 2–8 – Topical layer for the area; barrier-supporting moisturiser; mild keratolytic if thickening is present.
- Months 2–6 – Selected superficial peels or low-fluence laser sessions for stubborn cases; continued friction reduction.
- Long-term – Friction prevention as the maintenance plan; periodic topical cycles if recurrence appears.
Sequence for drug-induced pigmentation
- Visit 1 – Identify the suspect medication; coordinate with the prescriber for substitution where reasonable.
- Weeks 2–6 – Strict sun protection; supportive topicals as appropriate.
- Months 2–6 – Slow gradual fading once the trigger is removed; selected gentle peels if indicated.
- Long-term – Resolution often takes 6–12 months after the offender is stopped; patience and sun protection are the main tools.
Side-by-side comparison — what each modality does, what it does not
Use this table to understand how the main pigmentation modalities compare. The right combination for your skin will be picked at consultation based on type, depth, hormonal context, and Fitzpatrick skin tone — not from this table alone.
| Modality | Primary use | What it does well | What it does not address | Time to judge | Risk in Indian skin |
|---|---|---|---|---|---|
| SPF 50 PA+++ broad-spectrum | Universal foundation for every type | Blocks UVA, UVB; non-negotiable for any plan | Visible light unless tinted with iron oxides | Cumulative, daily | None — base layer for safety |
| Tinted mineral SPF (iron oxides) | Melasma, photo-distributed pigmentation | Adds visible-light protection that chemical SPF lacks | Internal upstream triggers | Cumulative, daily | None at correct shade |
| Hydroquinone (supervised) | Active phase melasma and PIH | Studied benchmark tyrosinase inhibitor | Long-term unsupervised use unsafe | 8–12 weeks at controlled concentration | Exogenous ochronosis if misused long-term |
| Kojic acid | Maintenance and combination phase | Gentler tyrosinase modulation; useful long-term | Severe dermal pigment alone | 12–16 weeks | Low; selected contact sensitivity |
| Azelaic acid 15–20% | Pregnancy-safe option, mild PIH and melasma | Mild tyrosinase + anti-inflammatory, generally well tolerated | Aggressive resistant melasma | 12–16 weeks | Low |
| Topical tranexamic acid | Melasma adjunct, vascular-component cases | Anti-vascular and anti-inflammatory layer | Solar lentigines | 12–16 weeks | Low; emerging evidence base |
| Topical retinoid (tretinoin, adapalene) | Combination with tyrosinase inhibitors | Accelerates epidermal turnover; amplifies other agents | Pure dermal pigment | 8–12 weeks | Initial irritation if not titrated |
| Niacinamide | Supportive layer in any plan | Reduces pigment transfer to keratinocytes | Primary tyrosinase activity | Cumulative | Very low |
| Vitamin C (L-ascorbic acid) | Daytime antioxidant, mild brightening | Reduces oxidative stress; supports SPF | Active resistant melasma alone | Cumulative; supportive | Stinging if over-strength |
| Mandelic / glycolic / kojic peels | PIH and surface tone refinement | Adjunct to topical course; gentler in Indian skin | Dermal melasma, lentigines base | 4–6 sessions at 3–4 wk intervals | Moderate if compressed intervals |
| Low-fluence Q-switched Nd:YAG (laser toning) | Selected resistant melasma after topicals plateau | Gradual modulation when used cautiously | Lentigines (different parameters required) | 4–8 sessions at 2–4 wk intervals | Significant — narrow safety window |
| Oral tranexamic acid | Resistant melasma after risk screening | Modulates vascular and inflammatory contributors | PIH, lentigines, friction pigmentation | 3–6 months | Thrombotic risk requires screening |
Why this table is not a shopping list
Each modality has a specific indication. Stacking three of them at high concentration does not produce three times the result; it usually produces irritation and rebound. The dermatologist sequences a layered combination at calibrated concentrations that interrupt multiple points in the pathway without overwhelming the skin barrier.
If you have this · Then we do this · Because
Pigmentation patterns lead to different first-line plans. The decision tree below maps the dominant patterns to their starting pathway and the reasoning behind each branch. Real plans usually combine 2–3 branches because most patients have mixed patterns.
Tyrosinase inhibitors and supportive topicals
Topicals are the foundation of most pigmentation plans. Each agent has a specific mechanism and a specific role; combination is usually more effective and better tolerated than any single agent at high concentration.
Hydroquinone — the studied benchmark
Hydroquinone (typically 2–4%) is one of the most studied tyrosinase inhibitors. Used short-term — usually 8–12 weeks — under dermatologist supervision with rest periods, it is effective and reasonably tolerated. Misuse — uncontrolled long-term use, very high concentrations, mixed creams of unknown composition — can cause exogenous ochronosis, contact dermatitis, or rebound pigmentation. The risks are about misuse, not the molecule itself.
Kojic acid
A fungal-derived tyrosinase inhibitor with a long history of cosmetic and dermatological use. Generally well tolerated; selected patients develop contact sensitivity. Used as an alternative or adjunct to hydroquinone, particularly for sustained treatment phases or as part of combination formulations.
Azelaic acid
A naturally occurring dicarboxylic acid (typically 15–20%) with mild tyrosinase-inhibition, anti-inflammatory, and gentle exfoliating effects. Considered safe in pregnancy under dermatologist supervision and is often the topical of choice when other agents must be paused. Slow but steady response over 12–16 weeks.
Arbutin
A glucose-bound form of hydroquinone that releases the active component slowly. Gentler tolerability than free hydroquinone, with reasonable evidence in mild to moderate pigmentation. Often included in combination products and as a maintenance agent after the active phase ends.
Topical tranexamic acid
An emerging topical option (2–5% formulations) with anti-vascular and anti-inflammatory effects in addition to tyrosinase modulation. Useful in melasma, particularly in combination with other agents. Tolerated well; evidence base is growing.
Topical retinoid
Tretinoin and adapalene accelerate epidermal turnover, helping pigment-laden cells migrate to the surface and shed faster. They are introduced gradually to limit irritation, paused around procedures, and resumed when the dermatologist clears. Retinoids amplify the effect of tyrosinase inhibitors when used together.
Niacinamide
Vitamin B3 derivative that limits the transfer of pigment from melanocytes to keratinocytes. Generally well tolerated, supportive rather than primary, and a sensible long-term ingredient in most pigmentation routines.
Vitamin C and other antioxidants
L-ascorbic acid and stable derivatives reduce oxidative stress and provide mild tyrosinase inhibition. Useful daytime layer that complements sunscreen and supports overall skin tone. Selected formulations are particularly relevant in Delhi pollution conditions.
Oral tranexamic acid for resistant melasma
Oral tranexamic acid is selectively prescribed for resistant melasma in patients who have already optimised topicals and sun protection without adequate response. It is not a first-line treatment and is not appropriate for every patient. The decision to start, the dose, and the monitoring schedule are clinical decisions made by the dermatologist after a thorough evaluation of individual risk.
How it works
Tranexamic acid is an antifibrinolytic that, in the context of melasma, modulates the vascular and inflammatory components of pigmentation. It does not act primarily on tyrosinase. The benefit is typically seen on layered melasma where epidermal and dermal components co-exist and topical-only plans have plateaued.
Eligibility and screening
Before starting, the dermatologist screens for thrombotic risk (personal or family history of clots, smoking, certain hormonal medication, known clotting disorders). Patients with significant risk are not candidates. Where eligibility is borderline, the prescriber co-ordinates with the patient's physician.
Dosing and duration
Typical regimens are at low controlled doses for defined periods — usually 3–6 months with periodic review. Earlier discontinuation if no response by the agreed milestone. Longer courses are used in selected cases under continued review.
What to expect
Patients who respond usually see lightening over 8–12 weeks, with continued improvement through 4–6 months. Maintenance after discontinuation depends on continued sun protection and topical care. Relapse is possible if upstream triggers persist; the plan addresses both.
Laser toning — low-fluence Q-switched Nd:YAG
Laser toning refers to low-fluence Q-switched Nd:YAG laser sessions delivered at gentle parameters across the face. It is one possible adjunct in selected pigmentation cases — not a first-line treatment. The fluence, spot size, frequency, and number of sessions determine whether it helps or harms; the same device used at the wrong settings can worsen melasma rather than improve it.
When it is considered
Low-fluence Q-switched Nd:YAG is considered in resistant melasma after topicals and sun protection have plateaued, or in selected mixed-pattern cases. It is used as an adjunct, with topicals continuing through the laser course. Patient selection is the safety-defining step.
What the protocol looks like
Typical courses are 4–8 sessions at 2–4 week intervals at conservative fluence and spot size. Pre-treatment topicals are usually in place for 2–4 weeks before the first session. Strict sun protection from at least 2 weeks before through 4 weeks after each session.
Risks of mis-calibrated laser toning
Aggressive Q-switched protocols designed for solar lentigines can worsen melasma by triggering rebound pigmentation or producing patchy de-pigmentation. The fluence threshold is narrow in Indian skin. Operator experience and parameter discipline are non-negotiable.
Why DDC uses it sparingly
The clinical literature is split on long-term benefit. We treat laser toning as one tool among several, used selectively when the case justifies it, with conservative parameters. Patients are not pressured into it; topicals + sun protection produce most of the meaningful change in most patients.
Chemical peels for pigmentation — by type and pattern
Peels are useful adjuncts when used at the right concentration and interval. The peel agent is matched to the pigmentation type and the patient's skin reactivity. Aggressive medium-depth peels carry significant pigmentation risk in Indian skin and are reserved for selected cases.
Glycolic acid
20–35% concentrations at 3–4 week intervals. Useful for diffuse photoageing, mild PIH, and as an adjunct to topical melasma plans. Pre-conditioning the skin with topicals for 2–4 weeks before improves tolerance and reduces post-procedure pigmentation risk.
Mandelic acid
A larger-molecule alpha-hydroxy acid that penetrates more slowly. Particularly well tolerated in Indian skin. Useful for early PIH, friction pigmentation, and as a gentler entry-level peel for sensitive patients.
Lactic acid
Hydrating alpha-hydroxy acid suitable for drier, more reactive skin. Mild brightening and surface refinement; often used in combination with other agents in formulations.
Kojic acid peels
Kojic-based peel formulations combine surface exfoliation with tyrosinase modulation. Useful in melasma adjunct and PIH; tolerance is generally good, response is gradual.
Salicylic acid
Lipophilic beta-hydroxy acid useful when pigmentation overlaps with comedonal tendency or oily skin. Selected for specific patient profiles, not as a generic pigmentation peel.
What we avoid
Aggressive medium-depth peels (high-strength TCA, phenol) on Fitzpatrick III–V skin without specific indication. Frequency higher than 3-week intervals. Stacking peels with same-week procedures. Peels on freshly waxed or threaded skin.
Risks of using the wrong laser or peel for the wrong pigmentation type
More patients arrive with worsened pigmentation from previous treatment than with under-treated baseline pigmentation. The reason is almost always a tool–condition mismatch: a laser or peel that would be appropriate for one pattern was applied to a different one. The list below describes the most common mismatches we see and what they produce.
Aggressive Q-switched protocols on melasma
Q-switched parameters designed for solar lentigines applied across melasma patches commonly trigger rebound pigmentation — the patch returns darker than baseline within weeks — or patchy de-pigmentation, leaving permanent uneven white spots within the original patch. Both are difficult to reverse. The right Q-switched protocol for melasma is low fluence, large spot, slow titration, and only after baseline topicals are in place.
IPL on Indian skin
Intense pulsed light is a broadband source originally designed for Fitzpatrick I–II skin. In Fitzpatrick III–V, IPL carries significant burn risk, paradoxical darkening, and worsening of melasma. We rarely use IPL for pigmentation in Indian skin and never as a first-line option. Patients sometimes book "photofacial" expecting brightening and arrive with hyperpigmented streaks that take months to settle.
Aggressive medium-depth peels on melasma
High-strength TCA, phenol, and similar medium-depth peels create deeper inflammation than Indian skin reliably tolerates without rebound. Used on melasma, they often trigger a worse flare than the patient started with. Selected superficial peels at calibrated concentrations are useful adjuncts; medium-depth peels are reserved for selected non-melasma indications.
Weekly peel courses
Compressed peel intervals — weekly or every 10 days — sound aggressive and reassuring. They produce inflammation and rebound pigmentation in Indian skin, not faster results. Peels at 3–4 week intervals respect epidermal turnover and barrier recovery; the slower interval is part of the safety protocol.
Stacking laser and peel in the same week
Two procedures in the same week produce overlapping inflammation and barrier disruption. The recovery curves cross before the first one completes; the cumulative response is rebound pigmentation rather than additive lightening. Sessions are spaced deliberately; "let us do laser plus a peel today to save a visit" is a marketing convenience, not clinical practice.
Microneedling on unstable melasma
Microneedling can be used cautiously as an adjunct in selected stubborn melasma cases to enhance topical penetration. Used aggressively or on unstable melasma, it triggers PIH and worsens the pattern. Most patients do not need microneedling for pigmentation alone; it is a layered scar-treatment tool more than a pigmentation tool.
Aggressive lasers on PIH that has not stabilised
PIH often improves substantially with topicals and time. Aggressive procedural intervention before the upstream inflammatory cause is settled simply re-fills the pigment. Wait for stability, then layer; do not lead with energy on a moving target.
Generic "fairness laser" packages
Some clinics sell pre-paid courses of unspecified "fairness laser" sessions without any pigmentation typing. These are usually IPL or aggressive Q-switched at standardised parameters across all skin types. The packaged structure pre-commits the patient to a number of sessions before the pattern is even diagnosed. We do not offer these and we wean patients off them when they have been mid-course elsewhere.
The principle
The same laser or peel used at different parameters on different conditions can be the right tool or the wrong one. The pattern, the depth, the prior history, and the skin type together drive the parameter choice. Buying "pigmentation treatment" without typing first is buying a tool without knowing what nail you have.
Coming off mixed creams safely
A significant fraction of Indian patients arrive on undisclosed chemist mixed creams — combinations of unidentified topical steroid, hydroquinone, and other agents — sold as "fairness" preparations. Procedures on this skin are unsafe; a structured weaning phase is part of the plan before primary pigmentation work can begin.
What mixed creams cause over time
- Skin thinning (atrophy) and visible blood vessels (telangiectasia)
- Steroid-induced rosacea — persistent redness and pustular flares
- Rebound pigmentation when the cream is stopped abruptly
- Exogenous ochronosis from chronic high-dose hydroquinone
- Hypertrichosis (extra fine hair) on the face
- Increased susceptibility to fungal and bacterial infections
How weaning is structured
- Honest disclosure at consultation — no judgment, just clinical context
- Gradual reduction in frequency over 4–8 weeks rather than sudden stop
- Substitute with safer barrier-supporting routine through the transition
- Anticipate and manage rebound flare with anti-inflammatory topicals
- Address steroid-induced rosacea separately if present
- Begin pigmentation pathway only once skin has stabilised — usually 8–12 weeks
Suitability for pigmentation treatment
Not every patient is ready for procedural pigmentation work at the moment of consultation. Some patients need a foundation phase of topicals and sun protection first. The dermatologist may defer procedures for safety reasons — this is the most common cause of "let us start with topicals" advice.
Sequencing pigmentation treatment around important dates
Indian patients often book pigmentation consultation with a fixed event in mind — a wedding, a milestone birthday, foreign travel, a wedding photo session. The plan respects that calendar. The framing below is the standard timeline we discuss for each window.
If your event is 4–6 months away
This is the most useful window for pigmentation. Sunscreen and topical foundation are established in the first month; a structured topical course runs for 8–12 weeks; selected superficial peels are spaced through the middle months; a final review 4 weeks before the event sets the maintenance plan. Most patients see meaningful lightening on photographs by the time of the event.
If your event is 6–12 months away
The full active phase completes with margin. For melasma, the layered topical course plus selected adjuncts sit comfortably within this window. For PIH, most cases improve substantially in the first 4–6 months, leaving the rest as maintenance. Stronger sessions sit early; lighter refinement and tinted-sunscreen optimisation sit closer to the event.
If your event is 8–10 weeks away
Foundation-only window. Strict sunscreen, tinted mineral SPF for melasma, gentle pigment-modulating topicals at calibrated concentrations, and one optional gentle superficial peel 4 weeks before the event. Aggressive interventions are deferred — the trade-off between marginal acceleration and visible reaction is not worth it this close to the date.
If your event is 4 weeks or less away
No new procedural intervention. The dermatologist confirms your routine, optimises sunscreen and barrier care, and addresses any acute irritation that could distract from the event-day appearance. The structured plan starts the week after rather than the week before.
If your wedding photo session is outdoors
Outdoor photo sessions add UV and visible light exposure exactly when you do not want melasma to flare. Tinted mineral sunscreen, wide-brim hat where styling allows, sunglasses between takes, and shaded-side framing during peak hours all help. The dermatologist may also schedule a final tinted-sunscreen demo session 1–2 weeks before so the right shade and finish under photo lighting is settled in advance.
If you are travelling internationally during the plan
Travel with sun exposure (beach, mountain, high altitude) is the single largest controllable risk to pigmentation work. Sunscreen reapplication every 2–3 hours, protective clothing, and shaded scheduling protect cumulative gains. Peels and laser sessions are scheduled at least 7–10 days before flight; the next session sits at least a week after return so any travel-induced flare is visible and addressable.
The honest framing
Pigmentation responds to consistent care over months. There is no genuinely safe way to compress 4 months of treatment into 4 weeks before an event. The right answer to "I have a wedding in 3 weeks" is rarely an aggressive new intervention — it is usually consistent foundation work and a planned start the week after.
Why Indian skin needs a different pigmentation protocol
Indian skin has higher baseline melanin and more reactive melanocytes. The same procedures and topicals that are safe in lighter skin can produce paradoxical pigmentation in Indian skin if used unmodified. The protocol below is built for Fitzpatrick III–V from the start.
Conservative procedural parameters
Energy levels, peel concentrations, pass counts, and spot density are reduced from textbook starting points and progressively titrated. The first session is always conservative; we build up only if response permits.
Pre-treatment topicals as standard
Tyrosinase inhibitors and gentle retinoid are typically started 2–4 weeks before procedures to lower baseline melanocyte activity and reduce post-procedure rebound pigmentation. This is not optional in Indian skin protocols.
Visible-light protection
Beyond UVA/UVB, visible light contributes to melasma in Indian skin. Tinted mineral sunscreen with iron oxides addresses this and is part of the routine for melasma patients, not a luxury choice.
Realistic outcome framing
Pressure to deliver "fairness" is a clinical risk factor — it pushes patients towards unsafe shortcuts. Honest goal-setting at consultation prevents this. The realistic outcome is even tone, lightened pigment, reduced relapse — not a different skin colour.
Layered combination approach
Single high-strength agents are riskier than combination at calibrated concentrations. Layered plans — multiple agents at moderate strength, applied at the right times — produce better and more durable response in Indian skin.
Long-term maintenance is non-negotiable
Indian skin pigmentation patterns are prone to relapse, especially melasma. The plan includes a maintenance phase from the start: continued sun protection, periodic topical cycles, annual review.
Delhi heat, pollution, sun — and your pigmentation plan
Delhi adds environmental pressures to any pigmentation plan: extreme summer heat, high winter particulate pollution, and persistent UV across the year. Each is built into the protocol rather than ignored.
Summer heat (April–July)
Heat dilates vessels, increases redness, and triggers melasma flares. Outdoor exposure within 48 hours of a procedure is more harmful in Delhi summer. Sessions in peak summer use longer intervals and stricter post-procedure cooling.
Monsoon humidity (July–September)
High humidity slows surface healing and can mimic seborrhoeic dermatitis flares. Light-formulation actives, brief use of barrier mist, and careful product selection through this season help — without disrupting the plan.
Winter pollution (October–February)
PM2.5 and PM10 levels in Delhi winter penetrate the upper skin and contribute to oxidative stress that amplifies pigmentation. Evening cleanse + antioxidant serum (where prescribed) reduce this load. Indoor air filtration helps in heavily polluted weeks.
UV across the year
Delhi UV index remains substantial through most of the year — even cool winter days. SPF reapplication every 3–4 hours when outdoors is the rule. Window-side and indoor exposure also count — UVA passes through glass.
Outdoor weddings and festivals
Delhi social calendars are dense and often outdoor. Plan major procedural sessions away from event-heavy weeks; the dermatologist will help schedule visible downtime around important dates.
Two-wheeler and car commute
Two-wheeler exposure adds wind and direct UV. A wide-brim helmet visor, sunscreen reapplication at noon, and a clean buff during peak pollution weeks reduce cumulative load. Car windows pass UVA — sunscreen still applies.
Sunscreen — what to use, how much, how often
Without consistent broad-spectrum sun protection, no topical or procedure produces durable improvement. The detail below is what we discuss with every pigmentation patient at consultation.
What to look for
- SPF 50 minimum, PA+++ minimum (PA++++ preferred)
- Broad spectrum — UVA and UVB protection
- Tinted mineral with iron oxides for melasma (visible-light protection)
- Texture suited to your skin — gel, lotion, cream — that you will actually use
- No common sensitisers in your specific allergy history
How much to apply
- Approximately ½ teaspoon for the face
- Approximately ¼ teaspoon for the neck
- Apply 15–20 minutes before sun exposure
- Reapply every 3–4 hours when outdoors
- Reapply after sweating heavily or towel-drying
- Even on cloudy days and indoors near windows
UVA vs UVB vs visible light
- UVB (290–320 nm): sunburn, immediate erythema; SPF rating addresses this
- UVA (320–400 nm): deeper penetration, photoageing, pigmentation; PA rating addresses this
- Visible light (400–700 nm): contributes to melasma in Indian skin; iron oxides in tinted sunscreens block this
- Infrared: contributes to oxidative stress; antioxidant serum supports here
Common reasons sunscreen fails
- Too little applied — most patients use a third of the right amount
- No reapplication during the day
- Rubbed off by towels, masks, or face touching
- Skipped on cloudy days or indoors
- Low SPF formulation that does not match Delhi UV index
- No visible-light protection on melasma-prone skin
UVB · UVA · visible light · infrared — and what protects against each
"Good sunscreen" rarely means the same thing across patients. The visible-light gap in standard chemical sunscreens is one of the most common reasons melasma patients flare despite daily SPF. The diagram below maps the wavelengths that drive pigmentation and which protective layer blocks each.
How treatment is calibrated for Fitzpatrick III–V
Pigmentation treatment carries its own pigmentation risk if mis-calibrated. Indian skin is more reactive than the rule-of-thumb assumes; the safer route is gentler, slower, and layered.
Lighter device settings
For peels and lasers, energy levels, concentrations, pass counts, and spot density are reduced from textbook starting points and progressively titrated. Conservative first-pass approach reduces post-procedure rebound pigmentation.
Longer intervals
Peels at 3–4 week intervals rather than weekly. Laser toning sessions at 2–4 week intervals depending on protocol. Compressing intervals raises inflammation and undoes the benefit.
Pre-treatment topicals
Tyrosinase inhibitors and gentle retinoid are often started 2–4 weeks before procedures to lower baseline melanocyte activity and reduce post-procedure rebound pigmentation.
Strict sun protection
Daily SPF 50 PA+++ from at least 2 weeks before through 4 weeks after every session. For melasma, ongoing daily sun protection is permanent — not a treatment-cycle measure.
No mixed creams
Combinations of unidentified steroid, hydroquinone, and other agents — sold by some chemists and online sellers — cause significant long-term harm. We do not prescribe these and we wean patients off them carefully when present.
Adverse-event protocol
Patients have a direct contact channel for any concerning reaction post-procedure. Unexpected reactions are reviewed by the treating dermatologist within 24–48 hours and the plan adjusted before further sessions.
What happens when pigmentation is left, hidden, or treated incorrectly
Pigmentation rarely improves on its own once established, especially in Indian skin. Several specific complications follow from delay, self-treatment with mixed creams, or aggressive procedural intervention that did not match the type. Each is preventable with early, correctly-typed dermatologist care.
Exogenous ochronosis
Blue-black or grey-brown discolouration from chronic, unsupervised, high-dose hydroquinone — usually through OTC mixed creams used over years. The pigment deposits in the dermis paradoxically and is difficult to reverse. Prevention is dermatologist-supervised, time-limited hydroquinone courses; once established, only cautious supportive care plus discontinuation slowly reduces visibility.
Steroid-induced rosacea and atrophy
Topical steroids in mixed creams cause skin thinning, telangiectasia (visible blood vessels), persistent redness, and pustular eruptions over months of use. The condition often flares on abrupt withdrawal, requiring a structured weaning phase before pigmentation pathway can begin. The consequence outlasts the original cream by 12–18 months.
Rebound pigmentation
Aggressive lasers, high-strength peels, and abrupt stopping of long-term topical agents can trigger pigmentation that returns darker than baseline. Most common with mis-calibrated Q-switched protocols on melasma and IPL on Indian skin. Recovery is slow — usually 6–12 months — and aggressive re-intervention compounds the problem.
Patchy de-pigmentation
Aggressive Q-switched protocols designed for solar lentigines applied to melasma can produce permanent uneven white spots within the original patch. Visible under all lighting conditions and usually irreversible. The damage is from the wrong tool used at the wrong settings — not from melasma itself.
Permanent dermal pigment in long-standing PIH
PIH that is repeatedly traumatised — picking, friction, repeated mixed-cream irritation — drops pigment from epidermis into dermis. Once established, response to topicals is slower and timelines extend from weeks to months. Early intervention before this conversion is significantly more effective than treatment after.
Burns and post-procedure scarring
IPL applied to Indian skin without parameter adjustment, aggressive peels stacked weekly, or laser settings imported from lighter-skin protocols can cause first or second-degree burns. The healing process leaves additional pigmentation and occasionally hypertrophic scarring at the burn site — a new condition added on top of the original pigmentation.
Photoageing layered on pigmentation
Years of unprotected UV add fine lines, uneven texture, and laxity that interact with established melasma or lentigines. Treatment is still effective but the total course often runs longer because both photoageing and pigmentation are being addressed in parallel rather than pigmentation alone.
Chronic flare cycle in untreated melasma
Untreated melasma cycles between mild and severe across years, driven by sun, hormonal events, and seasonal heat. Each flare deposits more pigment; each partial recovery leaves dermal residue. Over decades, the patch consolidates into a more pigmented, more dermal-component, more relapse-prone version of itself.
Psychological and social burden
Visible facial pigmentation in Indian context carries documented psychosocial weight — confidence loss, social avoidance, family pressure around "fairness". Untreated pigmentation extends this burden across years; the cost of waiting is rarely accounted for in the "should I treat?" decision but is part of the picture honestly.
Why early correctly-typed care matters
Epidermal melasma identified at first flare often resolves on a topical-led plan in 12–16 weeks. The same patient at 5 years post-flare with mixed-cream history may need 6–9 months of structured care plus weaning, plus selective procedural support. The clinical decision is not "do I have to treat?" but "is this the right window — and can I avoid making it worse first?".
What pigmentation treatment can — and cannot — achieve
Honest goal-setting is part of safety in pigmentation care. Below is what the dermatologist documents in the written plan as realistic versus unrealistic — separated cleanly so patients can choose to proceed with eyes open and avoid the "I expected more" trap that mid-marketed pigmentation services run on.
What pigmentation treatment can achieve
- Substantial lightening of recent epidermal PIH within 8–12 weeks
- Meaningful control of melasma — lighter patches, longer relapse intervals
- Visible reduction of solar lentigines through selective Q-switched plus topicals
- Significant fading of diffuse tanning over 3–6 months of consistent sun protection
- Even tone and reduced visibility of pigmented areas on photographs against baseline
- Recovery from mixed-cream damage with structured weaning over 8–12 weeks
- Quality-of-life improvement alongside skin improvement, supported by published evidence
- Long-term stability of gains when sun protection is maintained as a permanent layer
What pigmentation treatment cannot promise
- "Fairness" or a different complexion — treatment is for pigmentation, not skin colour
- Total resolution of melasma — chronic recurring biology cannot be turned off
- Identical lightening across all zones — central cheek often responds before lateral
- Compression of 4–6 month plans into "a few weeks" — collagen and pigment biology are slow
- Avoidance of relapse if sunscreen and trigger control slip after the active phase
- Same response to a friend's or relative's pigmentation plan — patterns and depths differ
- Complete reversal of exogenous ochronosis or steroid-induced atrophy from mixed creams
- Match to before-and-after photographs from another clinic, lighting, or skin type
How progress is judged honestly
Progress is judged against fixed-light baseline photographs at month 1, 3, 6, and 12 — not against daily mirror impression, not against online before-and-afters, and not against a target "shade" the patient has in mind. Photographs are objective; perception is not. The plan is adjusted at each review based on what the photographs actually show.
How to make your pigmentation consultation as productive as possible
The quality of information you bring shapes the quality of the plan you receive. A well-prepared first visit lets the dermatologist type your pigmentation accurately, identify hidden triggers, and build a realistic sequence on day one.
Bring all your current products — including the ones you are unsure about
Every product on your face — cleanser, toner, serum, moisturiser, sunscreen, makeup, and any "fairness", "brightening", or "scar removal" creams from chemists or online sellers. No judgement at consultation; the audit is for safety. Mixed creams of unknown composition shape the safe starting point and often need a structured weaning phase before active treatment can begin.
Bring photographs of your pigmentation at its worst
Most patients arrive on a relatively settled day or after applying makeup. Photographs taken in natural light without makeup, at the worst point of a recent flare, give the dermatologist information about pattern variability that a single visit cannot capture.
Note the timeline
When did the pigmentation first appear? Did it follow a specific event — pregnancy, OCP start, a holiday, a new product, a course of medication? Has it grown, faded, recurred, or stayed stable? Are there seasonal patterns? The story is often more diagnostic than the appearance alone.
Note hormonal history
Pregnancy, breastfeeding status, current OCP or hormonal IUD, perimenopause symptoms, irregular cycles, PCOS features, thyroid history. Pigmentation often responds to hormonal context; the plan reflects it. Self-discontinuation of hormonal medication is not advised — coordination with your prescriber is built into the plan when needed.
Note medication and medical history
All current medications including OTC supplements. Photosensitising drugs (some antibiotics, antimalarials, NSAIDs). Recent or current chemotherapy. Autoimmune conditions. Thrombotic history (personal or family) — relevant if oral tranexamic acid may be considered later.
Note sun and heat exposure pattern
Daily commute (vehicle type, window film, helmet, time outdoors). Occupational sun exposure. Travel to high-altitude or beach destinations in the last six months and planned in the next six. Kitchen heat exposure (cooks, home cooks). Hot yoga or sauna habits. Each shapes the trigger-control side of the plan.
Bring relevant blood reports if available
Recent thyroid, hormonal, or ferritin / vitamin B12 panels. Not every pigmentation patient needs investigations, but where the history points to a contributor, having reports ready saves a follow-up visit.
Plan your calendar honestly
Major events, weddings, work travel, exam periods, and pregnancy planning across the next 6–12 months. The plan is sequenced around your real calendar. Aggressive intervention 4 weeks before a wedding is rarely the right move; foundation work and a planned start the week after often is.
List previous treatments
Topicals, peels, lasers, IPL, microneedling, oral therapies — what was used, when, how long, and what you observed during and after. This context helps the dermatologist judge what has and has not been tried and avoid repeating an approach that already plateaued.
Questions to ask your dermatologist
- What pigmentation type do I have, and what depth?
- What are my main triggers, and which can I control?
- Is my current sunscreen routine adequate? Should I switch to tinted mineral?
- Which topicals will I start with, and at what concentration?
- What is the realistic timeline for visible improvement?
- Will I need procedural adjuncts — and if so, when?
- What does maintenance look like once the active phase is done?
The pathway when previous treatment did not deliver
A meaningful fraction of patients arrive having tried multiple products, courses, or clinics before consultation. Frustration is normal. The visit is structured to identify what was actually tried, what was missed, and where the real lever is — rather than layering more treatment on a flawed foundation.
Common reasons prior pigmentation treatment underperformed
- No typing — same plan applied across melasma, PIH, lentigines, and tanning
- Inconsistent or under-applied sunscreen — the foundation was never solid
- Mixed cream of unknown composition causing rebound and ochronosis
- Aggressive laser protocol applied to melasma, triggering rebound or de-pigmentation
- Single-agent topicals at high concentration rather than layered combinations
- Peels at compressed intervals causing inflammation rather than fading
- Untreated upstream cause — friction, eczema, ongoing acne, photoreactive product
- Hormonal driver not addressed (OCP, IUD, perimenopause)
- Plan stopped at first visible improvement, allowing relapse
- Vitamin or iron deficiency unaddressed in selected cases
How the assessment is rebuilt
- Independent re-typing in standardised lighting with dermoscopy
- Wood's lamp where the depth question is open
- Side-by-side review of any photographs the patient has from before and during prior treatment
- Listing what was actually used — products, peels, laser, mixed creams — versus what should have happened given the type
- Honest framing of how much residual pigmentation is improvable now and how much is fall-out from prior treatment that needs slow recovery
- Fresh written plan starting with the foundation: sun protection, gentle barrier, and pigment-modulating topicals
- Procedural adjuncts considered only after foundation stabilises
- Hormonal coordination with prescriber where relevant
- Investigations only where history points to a contributor
How real patients usually arrive — and how the assessment changes
Most pigmentation patients have already done something before booking — researched online, tried products, used "fairness" preparations, had a procedure elsewhere, or lived with the pigmentation for years. The archetypes below are the most common arrival patterns at DDC pigmentation consultation.
"This fairness cream worked at first then made everything worse."
Undisclosed combinations of steroid, hydroquinone, and other agents produce thinning, telangiectasia, rebound pigmentation, and steroid rosacea over months to years. The plan opens with structured weaning over 4–8 weeks before primary pigmentation pathway can begin.
"My pigmentation is worse after laser at another clinic."
IPL or aggressive Q-switched protocols on Indian melasma commonly trigger rebound darkening or patchy de-pigmentation. Recovery is slow — usually 6–12 months — and requires stopping aggressive intervention. Topicals and sun protection rebuild the foundation; further procedures are deferred.
"It started during pregnancy and never fully cleared."
Pregnancy-onset melasma (chloasma) often partially settles after delivery but can persist or recur. The plan starts cautiously during breastfeeding with pregnancy-safe topicals (azelaic acid, sunscreen) and expands to the full toolbox once breastfeeding ends.
"My neck and underarms keep getting darker no matter what I try."
Friction-zone pigmentation often gets treated as a primary pigmentation disease when the actual lever is upstream — clothing seam, jewellery clasp, hair-removal habit, scrubbing. Identifying the friction source is the first step; topicals support but cannot replace it.
"I have tried every product the chemist suggests."
OTC pigmentation products usually under-deliver because they were not matched to a typed pattern. The audit identifies what was used, what type of pigmentation is actually present, and pivots to a layered prescription combination at calibrated concentrations.
"My wedding is in six months and I want clearer skin."
Six months is a usable window. Sunscreen and topical foundation in month 1; structured topical course through month 4; selected superficial peels in middle months; final review 4 weeks before the event. Honest framing of how much improvement is realistic in the window is part of the visit.
Self-care during pigmentation treatment
Roughly 70% of the work happens at home, every day, between visits. The home routine is not optional — it is the foundation that procedures build on. Procedures without consistent home care produce short-lived results.
Daily essentials
- Sunscreen SPF 50 PA+++ every morning, reapplied every 3–4 hours outdoors
- Tinted mineral sunscreen if you have melasma (visible-light protection)
- Gentle non-foaming cleanser if your skin is reactive
- Barrier-supporting moisturiser morning and night
- Prescribed actives only at the prescribed cadence
- Wide-brim hat and sunglasses for outdoor time
What to avoid
- Aggressive scrubs, brushes, or facial cleansing devices
- OTC brightening / fairness creams of unknown composition
- Saunas, steam, hot showers, or kitchen heat without skin protection
- Mixing multiple new actives at once
- Stopping sunscreen "because it is cloudy" or "because I am indoors"
- Switching products mid-plan without telling the dermatologist
- Laser parlours and "fairness facials" outside dermatology supervision
Realistic multi-month journey
Pigmentation improves gradually. The sequence below is the typical course for a patient with mixed melasma and post-inflammatory marks, starting on a topicals-led plan with selective adjuncts.
Week 0 — Consultation
Pigmentation typing, dermoscopy, Wood's lamp where indicated, photographs, history review, and a written 8–12 week starter plan. Sunscreen and home routine reviewed. Pre-treatment topicals started.
Week 4 — First check-in
Tolerance of topicals reviewed. Adjustments to concentration or frequency made. First superficial peel, if indicated. Patient reinforced on sunscreen consistency — this single step accounts for most early progress.
Week 8–12 — Mid-plan review
Comparison photographs reviewed against baseline. Visible improvement is typically seen in post-inflammatory marks first; melasma response is slower. Plan adjusted — adjuncts added, topicals modified, or oral therapy considered for resistant cases.
Month 4–6 — Refinement
For resistant melasma, oral tranexamic acid considered after risk assessment. Selective low-fluence laser toning for stubborn cases by an experienced operator. Topicals continue throughout. Sun and trigger control reinforced.
Month 6–12 — Stabilisation
Most early post-inflammatory marks resolve by this stage. Melasma is usually substantially lighter. Maintenance plan set — typically continued sun protection plus periodic topical cycles. Maintenance is not optional, especially for melasma.
Long-term — Maintenance and relapse prevention
Melasma is a chronic recurring condition. Daily sun protection is permanent. Periodic dermatologist review at 6–12 months keeps the plan current. Hormonal events (pregnancy, OCP changes, perimenopause) can trigger flare and need fresh review.
Maintenance and relapse prevention
Once the active 3–6 month plan completes, the goal shifts to protecting the gains and identifying early signs of flare before pigmentation re-establishes.
What maintenance looks like
- Daily sun protection — permanent for melasma, daily for any patient with photoageing
- Periodic topical cycles — usually 8–12 weeks of tyrosinase inhibitor and retinoid every 6–12 months
- Continued antioxidant layer in pollution-heavy seasons
- Annual photographic review with the dermatologist
- Selective single-session topicals or peels for early flare detection
When to re-engage actively
- Visible darkening of previously stable areas
- Pregnancy, OCP change, or perimenopause — hormonal triggers
- Significant new sun exposure (extended outdoor activity)
- New medication started that may be photosensitising
- Relapse after 6+ months of stability
Relapse prevention as a permanent layer of care
For melasma in particular, relapse is biology, not failure. The triggers — UV, hormones, heat, friction, certain medications — do not disappear after treatment. The most successful patients are not those with the most aggressive active phase, but those whose maintenance phase actually runs every day for years. The framework below is what we set up at the end of the active plan.
The four levers of long-term control
- Sun protection — daily SPF 50 PA+++ broad-spectrum, tinted mineral for melasma, reapplied every 3–4 hours outdoors. This is permanent.
- Trigger control — heat exposure, hot showers, kitchen heat, hot yoga, photo-reactive products, friction sources. Periodic audit at follow-ups.
- Maintenance topicals — periodic 8–12 week cycles of pigment-modulating topicals every 6–12 months, calibrated to flare risk.
- Hormonal awareness — recognising pregnancy, OCP changes, perimenopause, and thyroid shifts as flare windows that may need fresh review.
What a successful maintenance year looks like
- Daily sunscreen application logged in habit, not negotiated
- Tinted mineral sunscreen kept stocked and reapplied during the day
- Antioxidant serum continued through pollution-heavy seasons
- Periodic 8–12 week topical cycles spaced through the year
- Annual photographic comparison at the dermatologist visit
- Early re-engagement at first signs of flare rather than waiting until pigment is established
Common reasons maintenance slips
- Visible improvement reaches "good enough" and patient stops sunscreen
- Topical cycles dropped during life events or travel
- Switch to a different sunscreen that is not actually broad-spectrum
- Tinted mineral replaced with regular chemical sunscreen for "feel"
- New cosmetic product introduced without disclosure of its photo-reactivity
- Hormonal change (pregnancy, OCP) without alerting the dermatologist
- Heat exposure habits return — hot showers, hot yoga, sauna, kitchen work
What to do when relapse appears
- Photograph the affected area for objective comparison with prior baseline
- Audit sunscreen use over the prior 4–8 weeks honestly
- Identify any new product, medication, or trigger event
- Re-engage early — fresh patches respond to topicals faster than established ones
- Plan a topical cycle of 8–12 weeks with the dermatologist; selected superficial peel if indicated
- Avoid leaping to aggressive procedural intervention as a first response
The patient-facing principle
"It came back" is not "treatment failed". For melasma especially, relapse is built into the biology of the condition. The successful long-term plan recognises this in advance and is designed to make flares smaller, less frequent, and easier to settle. Permanence is in the maintenance, not in total resolution.
What we do not do — and why
Setting expectations honestly at consultation is part of safety. Below are the practices we explicitly avoid and the reasons why.
No "fairness" promises
Fairness products rely on aggressive bleaching, undisclosed steroids, or unproven claims — and they harm Indian skin in the long term. We treat pigmentation, not skin colour. The realistic outcome is even tone, not a different complexion.
No undisclosed mixed creams
Combinations of unidentified steroid, hydroquinone, and other agents cause thinning, telangiectasia, rebound pigmentation, and steroid-induced rosacea. We do not prescribe these; we wean patients off them carefully.
No aggressive lasers on melasma
High-fluence Q-switched protocols, IPL on melasma-prone skin, and aggressive resurfacing are well documented to worsen melasma. We use Q-switched only at low fluence and only when topicals have plateaued.
No compressed peel intervals
Weekly peels in Indian skin produce inflammation and pigmentation, not faster results. Peels are at 3–4 week intervals. The interval is part of safety, not a flexibility offer.
No oral tranexamic without screening
Oral tranexamic acid carries thrombotic risk that needs careful screening before prescription. We do not prescribe based on patient request alone.
No quick-fix language
"Removes pigmentation in 7 days" claims are a marketing pattern, not a clinical reality. Honest timelines are part of how we earn trust.
Pigmentation myths — and what is actually true
Pigmentation myths are particularly persistent in Indian skincare conversation, often pushed by social media and unregulated products. The list below addresses the most consequential ones we see at consultation.
The questions and feelings most people don't say out loud
Pigmentation has emotional weight in Indian context — partly due to cultural fairness pressure, partly due to its visibility. The list below is what patients have told us at consultation when given room to do so.
"Am I asking for fairness, not treatment?"
Pigmentation is a real medical condition with documented psychosocial impact. Treating it is medical care, not vanity. The clinical goal is even tone and reduced visibility, not changing your complexion.
"Will my pigmentation come back?"
For melasma, yes, often — that is its biology. The plan addresses this honestly: maintenance is built in from day one, and relapse triggers are reviewed. For PIH and lentigines, durable response is more common.
"Can I look like the before-and-after photos online?"
Online before-and-afters are usually best-case selections, sometimes with lighting changes. The honest answer is your photographs against your baseline, reviewed at month 3 and month 6, will show meaningful change — not instagram contrast.
"Why do I keep buying products that do not work?"
Marketing is sophisticated and pigmentation is a high-anxiety category. The product cycle — new bottle, hope, no result, new bottle — is common. The consultation breaks this by typing what you have and matching the agent to it.
"Should I stop my OCP / hormone medication?"
Not on your own. We co-ordinate with your gynaecologist or physician about hormonal options if pigmentation is hormonally driven. Self-discontinuing prescribed medication has consequences beyond skin.
"My family is pressuring me about my skin tone."
This is more common than most patients say. The conversation is part of the consultation when you raise it. The treatment plan addresses pigmentation, not family expectations; honest goal-setting protects you from unsafe shortcuts.
What makes DDC different for pigmentation
Pigmentation is one of the most heavily marketed dermatology categories in India and one of the easiest to deliver poorly because the harm signals are slow. The principles below are how DDC operates structurally — not slogans, but enforced practice.
Type before treat
Every patient is typed and depth-assessed before any procedure or active topical is offered. Melasma, PIH, lentigines, friction, drug-induced — each gets a different starting plan. No standard package.
Indian skin first
Parameters and concentrations are calibrated for Fitzpatrick III–V from the start. Western or East Asian protocols are not applied unmodified to Indian skin at DDC.
Sunscreen-led foundation
SPF 50 PA+++ is audited, not just recommended. Tinted mineral with iron oxides is standard for melasma. The single most evidence-backed intervention is treated as protocol, not lifestyle suggestion.
No aggressive lasers on melasma
Aggressive Q-switched and IPL protocols are not used on melasma. Low-fluence laser toning is selective, by experienced operator only, and only after topicals have plateaued.
No undisclosed mixed creams
We do not prescribe undisclosed combinations of steroid, hydroquinone, and other agents. We wean patients off them carefully when they have been using them, before primary pigmentation work begins.
Calibrated intervals, not weekly
Peels at 3–4 week intervals; laser toning at 2–4 week intervals. Compressing intervals increases inflammation and rebound in Indian skin. The interval is part of the safety protocol.
Oral therapy with screening
Oral tranexamic acid is selectively prescribed only after thrombotic risk screening. Not given on patient request alone. Dose, duration, and monitoring are documented in writing.
Honest goal-setting
Realistic outcomes documented in writing — managed control of melasma, durable lightening of PIH, even tone, reduced relapse. No "fairness" claims. No "removal in N sessions" promises.
How DDC pigmentation treatment is run behind the scenes
A pigmentation plan is only as safe as the systems supporting it. Below is the operational layer most patients never see — but it is what separates supervised dermatology care from cosmetic-room aesthetics.
Standardised photographic protocol
Every pigmentation patient has baseline photographs at the first visit: front, oblique, and lateral views, neutral expression, no makeup, identical natural-light positioning. Wood's lamp or polarised dermoscopy frames are added where indicated. Repeat photographs are taken at month 1, 3, 6, and 12 with the same camera, distance, and lighting so change can be judged objectively.
Documented written plan
Every consultation generates a written clinical note: pigmentation type, depth assessment, hormonal context, prior treatment history, topical sequence, peel or laser intervals if applicable, oral therapy plan if applicable, and review dates. Documentation supports continuity across branches and is available to the patient on request.
Multi-doctor review for difficult cases
Cases with mixed-cream history, steroid-induced rosacea, exogenous ochronosis, prior IPL or Q-switched complications, suspected drug-induced pigmentation, and resistant melasma being considered for oral tranexamic acid are presented at internal clinical review with a second qualified dermatologist before treatment escalation.
Procedure-room safety summary
Single-use peel applicators per patient, EN-standard medical-grade gloves, alcohol-based skin preparation, sharps disposal per Indian Bio-Medical Waste Rules. Q-switched Nd:YAG handpieces are calibrated on the manufacturer's recommended schedule and tested with a power meter before sessions involving Fitzpatrick IV–V patients.
Oral tranexamic acid screening checklist
Personal and family thrombotic history, current hormonal medication, smoking status, known clotting disorders, recent surgery — all documented before prescription. Borderline eligibility triggers coordination with the patient's physician. The prescription is dose-controlled, time-limited, and reviewed at fixed intervals.
Mixed-cream weaning protocol
For patients arriving on undisclosed mixed creams, a structured weaning is built before active pigmentation pathway begins: gradual frequency reduction over 4–8 weeks, anti-inflammatory and barrier-supporting substitution through the transition, anticipation of rebound flare, separate management of any steroid-induced rosacea. Pigmentation pathway begins only after skin stabilises.
Staff role separation
Clinical decisions — diagnosis, typing, modality choice, parameter setting, prescription — are made and performed only by qualified dermatologists registered with the Delhi Medical Council or equivalent state council. Trained clinical assistants prepare the patient, take baseline photographs, and assist during procedures under direct dermatologist supervision. Reception staff handle scheduling and never give clinical advice.
Branch consistency and re-entry
All branches use the same pigmentation protocols, same device selection criteria, and same documentation standards. Photo records, clinical notes, and the written plan transfer with the patient. Patients who pause treatment for any reason — pregnancy, illness, financial reasons, travel — are re-evaluated freshly on return rather than resumed at the previous step. Re-entry is treated as a new consultation.
What pigmentation before-and-after photos can prove — and what they cannot
Photographs and testimonials are useful supportive evidence. They are not predictive of your outcome. Pigmentation in particular is vulnerable to lighting tricks; this section explains what to look for so you can read clinic photographs critically — including ours.
What a single before-and-after pair proves
It proves that a particular patient, on a particular plan, with a particular pigmentation type, depth, hormonal context, and adherence pattern, achieved that specific outcome. It does not prove the same plan will produce the same outcome on different skin. Pigmentation response is multifactorial; predictors include pattern, depth, hormonal context, prior treatment, Fitzpatrick skin tone, and adherence — none visible in a single photograph pair.
What an aggregated photograph set can suggest
A larger set covering a range of types, depths, and skin tones can suggest the realistic distribution of outcomes — best-case, average-case, partial-case, and non-responder. This is more honest than showcasing only best-case results. When DDC publishes pigmentation before-and-after evidence, it is presented as a distribution rather than a highlight reel.
Why lighting changes the story dramatically
Pigmentation is uniquely vulnerable to lighting effects. Soft frontal lighting hides texture; warm light flattens contrast; cool light accentuates pigment; underexposure makes skin look lighter. Two photographs of the same patient on the same day under different lighting can look like complete clearing without anything having changed. DDC clinical photographs use standardised lighting; pairs you see online elsewhere often do not.
How DDC governs pigmentation photographs
Patient photographs are taken in a controlled clinical setting with consistent lighting, distance, and angle so change is real, not a lighting effect. Stored in the clinical record only. Public use requires separate written consent. Identifying features are obscured unless the patient has specifically consented to identifiable use. No photograph is filtered, smoothed, or edited beyond cropping and standard exposure normalisation.
How testimonials are used here
Patient quotes, when used, describe their personal experience of the consultation, the treatment, and the clinic. They do not function as efficacy claims. Phrases that imply complete clearance or assured fair skin are not how DDC presents testimonials, even when individual patients describe their experience in those terms. Testimonials are edited only to remove identifying details and overclaiming language.
How to read pigmentation before-and-afters elsewhere
Look for: same lighting in both frames, same camera angle and distance, no visible filter or smoothing, time interval clearly stated, and disclosure of what was used. If any of these are missing, treat the pair as marketing rather than clinical evidence. "Fairness in 7 days" before-and-afters almost always rely on lighting, makeup, or a filter rather than actual pigmentation change.
Specialist dermatologists — qualified, registered, experienced
All DDC doctors hold formal dermatology qualifications and medical council registration. This information is verified and publicly confirmable. No unqualified practitioners perform treatment.
Dr Chetna Ghura
MBBS, MD Dermatology
16 years experience
Medical Reviewer · Pigmentation & cosmetology
Dr Kavita Mehndiratta
MBBS, DVD, FRHS, MIADVL
20 years experience
Skin care · Laser procedures
Dr Sachin Gupta
MBBS, MD Dermatology
Dermatology specialist
Acne · Scars · Laser · Vitiligo
Dr Aakansha Mittal
MBBS, D.D.V.L, MIADVL
3 years experience
Skin · Hair · Nails · Allergy
Dr Rinki Tayal
MBBS, DDVL Dermatology
2 years experience
Dermatology · Hair regrowth
Starting from ₹1,999 — final cost depends on your plan
Pricing is intentionally not packaged. Pigmentation treatment varies substantially by type, severity, modality mix, and duration. The consultation produces a written plan with a transparent cost breakdown — not a single sticker price.
What ₹1,999 includes
- 30–45 minute dermatologist consultation
- Pigmentation typing and dermoscopy where indicated
- Wood's lamp examination where relevant
- Standardised baseline photographs in fixed lighting
- Written treatment plan with sequence and intervals
- Sunscreen, trigger-control, and home-routine guidance
What changes the total cost
- Topical-only versus combination plans
- Number and type of peels in the course
- Whether laser toning or selective procedural adjuncts are added
- Use of oral tranexamic acid or related systemic therapy
- Total duration — most plans run 3–6 months at minimum
- Investigations recommended in selected cases (thyroid, hormone panel, ferritin)
Why no fixed package?
An ₹X,000 "all-in pigmentation package" sounds simple but produces a worse outcome for most patients. Pigmentation type dictates the right tool combination; pre-buying a fixed number of one modality often means under- or over-treating individual patterns. Pay-per-session with clear estimates aligns cost with actual clinical need.
Glossary of pigmentation terms
Quick reference for the terms used on this page and in your consultation notes.
- Melanin
- The pigment produced by melanocytes that gives skin, hair, and eyes their colour. Variation in production and distribution accounts for normal skin-tone differences and pigmentation conditions.
- Melanocyte
- The cell in the basal layer of the epidermis that produces melanin and transfers it to surrounding keratinocytes via dendrite-like projections.
- Keratinocyte
- The predominant cell of the epidermis. Receives pigment packets from melanocyte dendrites and carries them to the surface during normal turnover.
- Tyrosinase
- The rate-limiting enzyme in melanin synthesis. Many topical pigmentation agents — hydroquinone, kojic, arbutin, azelaic, tranexamic, vitamin C — work by inhibiting or modulating this enzyme.
- Eumelanin / Pheomelanin
- The two main forms of melanin. Eumelanin (brown-black) provides most UV protection; pheomelanin (red-yellow) is more reactive. Indian skin is predominantly eumelanin-rich.
- Melasma
- Symmetric brown or grey-brown patches, typically on the face, often hormonally driven and sun-sensitive. Chronic and recurring; managed rather than cured.
- Chloasma
- The colloquial name for pregnancy-onset melasma — "the mask of pregnancy". Often partially settles after delivery; persistent cases respond to standard melasma management once breastfeeding ends.
- MASI
- Melasma Area and Severity Index — a research-grade scoring tool used to quantify melasma extent and intensity for trial reporting.
- PIH (post-inflammatory hyperpigmentation)
- Flat dark marks left after any inflammatory event in the skin. Pigment, not texture. Usually improves with topicals and time once the upstream inflammation is settled.
- PIE (post-inflammatory erythema)
- Flat red or pink marks from dilated capillaries after inflammation. Vascular pathway separate from PIH; often co-exists in Indian skin.
- Solar lentigines
- Brown patches and freckle-like spots caused by cumulative UV exposure, typically on face, hands, and chest from late thirties onwards. Sharp-edged and stable, distinct from melasma.
- Ephelides (freckles)
- Small flat tan or brown spots that darken in summer and lighten in winter. Usually present from childhood; treatment is largely sun protection.
- Hori's macules
- Acquired bilateral nevus of Ota-like macules — bilateral grey-brown to blue-grey patches on the cheeks. Look like melasma but are dermal pigment with different management.
- Lichen planus pigmentosus
- An inflammatory pigmentation pattern presenting as dark grey-brown patches, often on face and neck. Distinct from melasma; needs different management.
- Wood's lamp
- A long-wavelength UV lamp used selectively to differentiate epidermal from dermal or mixed pigmentation. Epidermal pigment shows accentuated contrast under the lamp; dermal pigment does not.
- Dermoscopy
- Magnified examination of the skin surface and superficial layers using a polarised light dermatoscope. Reveals pigment patterns and vascular features invisible at conversational distance.
- Fitzpatrick skin type
- A 6-point scale describing skin's response to UV exposure. Indian skin is typically Fitzpatrick III, IV, or V. Higher types have higher pigmentation reactivity and require gentler protocols.
- Hydroquinone
- The most studied tyrosinase inhibitor. Effective and reasonably tolerated short-term (8–12 weeks) under dermatologist supervision. Misuse — uncontrolled long-term use, mixed creams of unknown composition — causes specific harms.
- Kojic acid
- A fungal-derived tyrosinase inhibitor with a long history of cosmetic and dermatological use. Generally well tolerated; useful as alternative or adjunct to hydroquinone, especially in maintenance phases.
- Azelaic acid
- A naturally occurring dicarboxylic acid (typically 15–20%) with mild tyrosinase-inhibition, anti-inflammatory, and gentle exfoliating effects. Safe in pregnancy under dermatologist supervision.
- Tranexamic acid
- An antifibrinolytic used topically (2–5%) and orally (selectively, after risk screening) for melasma. Modulates the vascular and inflammatory components of pigmentation.
- Niacinamide
- Vitamin B3 derivative that reduces pigment transfer from melanocyte to keratinocyte. Generally well tolerated; supportive rather than primary in pigmentation plans.
- Tinted mineral sunscreen
- A sunscreen formulation containing iron oxides that provides visible-light protection in addition to UV protection. Particularly relevant for melasma in Indian skin.
- Visible light
- Wavelengths 400–700 nm. Contributes specifically to melasma in Indian skin in a way that standard chemical sunscreens do not block. Iron oxides are the practical answer.
- Q-switched Nd:YAG
- A specific laser type used at low fluence ("toning") as a selective adjunct in melasma, or at higher fluence for solar lentigines. Different parameters for different conditions; the same device at the wrong settings can worsen melasma.
- Fluence
- Energy density delivered per pulse by a laser, measured in joules per square centimetre. The fluence threshold is narrow in Indian skin; mis-set fluence is the most common cause of laser-induced pigmentation worsening.
- IPL (intense pulsed light)
- A broadband light source originally designed for Fitzpatrick I–II skin. Significant burn and rebound risk in Fitzpatrick III–V; rarely the right choice for pigmentation in Indian skin.
- Exogenous ochronosis
- A blue-black or grey-brown discolouration caused by chronic high-dose hydroquinone misuse — usually from unsupervised mixed-cream use over years. Slow to reverse.
- Mixed cream
- An undisclosed combination of topical agents — usually steroid, hydroquinone, retinoid, sometimes antibiotics — sold as "fairness" preparations. Causes thinning, telangiectasia, rebound pigmentation, and steroid-induced rosacea over time.
- Steroid-induced rosacea
- Persistent redness and pustular eruptions caused by long-term topical steroid use on the face. Common in patients arriving on mixed creams; needs structured weaning before pigmentation pathway can begin.
- Pre-treatment topical phase
- The 2–4 weeks before a procedural session during which pigment-modulating topicals are introduced to lower baseline melanocyte activity. Standard practice in Fitzpatrick III–V skin.
Honest answers before you book
Common questions about pigmentation treatment — typing, sunscreen, topicals, peels, laser toning, oral therapy, maintenance, and Indian-skin context. Every question on this page is pigmentation-specific.
How do I tell melasma from post-inflammatory hyperpigmentation?
Why is pigmentation more persistent in Indian skin?
Is sunscreen really that important for pigmentation?
What is a Wood's lamp examination?
What topical agents are used for pigmentation?
Are chemical peels safe for pigmentation in Indian skin?
What is laser toning, and is it the same as a regular laser?
Is Q-switched Nd:YAG safe for melasma?
Can pigmentation be cured permanently?
Why is hydroquinone often prescribed but discussed cautiously?
What is the role of oral tranexamic acid in melasma?
Can pregnancy or hormonal medication trigger pigmentation?
How long until I see visible improvement?
How is relapse prevented?
How much does pigmentation treatment cost?
Are there safe options during pregnancy?
How is dark-circle pigmentation different?
Why do friction-zone areas (underarms, inner thighs) darken?
Is IPL safe for pigmentation in Indian skin?
What about microneedling for pigmentation?
Why does melasma keep coming back?
What is the role of vitamin C in pigmentation?
Does diet really affect pigmentation?
When are blood investigations recommended?
What is exogenous ochronosis?
I have a wedding in 6 months — can pigmentation realistically improve in time?
How is melasma different in epidermal versus dermal versus mixed forms?
I had IPL elsewhere and my pigmentation looks worse — what now?
Why does my melasma flare every summer despite sunscreen?
Is microneedling useful for pigmentation?
What if I have multiple pigmentation types together?
How is dermoscopy used in pigmentation diagnosis?
Why are my underarms and inner thighs dark?
Public reference layer — pigmentation
This page draws on internationally recognised dermatology references for educational accuracy, with sources specific to pigmentary disorders. It does not reproduce clinical guidelines verbatim and does not constitute personal medical advice.
- 1Sheth VM, Pandya AG. Melasma: a comprehensive update — part I & II. Journal of the American Academy of Dermatology. 2011;65(4):689–718.
- 2Sarkar R, Arora P, Garg VK, Sonthalia S, Gokhale N. Melasma update. Indian Dermatology Online Journal. 2014;5(4):426–435.
- 3Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. Journal of Clinical and Aesthetic Dermatology. 2010;3(7):20–31.
- 4Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. Journal of the American Academy of Dermatology. 2006;54(5 Suppl 2):S272–S281.
- 5Lakhdar H, Zouhair K, Khadir K, et al. Evaluation of the effectiveness of a broad-spectrum sunscreen in the prevention of melasma. Journal of the European Academy of Dermatology and Venereology. 2007;21(6):738–742.
- 6Kang HY, Bahadoran P, Ortonne JP. Reflectance confocal microscopy for pigmentary disorders. Experimental Dermatology. 2010;19(3):233–239.
- 7Bala HR, Lee S, Wong C, Pandya AG, Rodrigues M. Oral tranexamic acid for the treatment of melasma: a review. Dermatologic Surgery. 2018;44(6):814–825.
- 8Wattanakrai P, Mornchan R, Eimpunth S. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for the treatment of facial melasma in Asians. Dermatologic Surgery. 2010;36(1):76–87.
- 9Kim EH, Kim YC, Lee ES, Kang HY. The vascular characteristics of melasma. Journal of Dermatological Science. 2007;46(2):111–116.
- 10Mahmoud BH, Hexsel CL, Hamzavi IH, Lim HW. Effects of visible light on the skin (relevant to melasma and post-inflammatory hyperpigmentation). Photochemistry and Photobiology. 2008;84(2):450–462.
- 11Castanedo-Cazares JP, Hernandez-Blanco D, Carlos-Ortega B, et al. Iron oxide–containing sunscreen for melasma: a randomized comparison. Photodermatology, Photoimmunology & Photomedicine. 2014;30(1):35–42.
- 12Verallo-Rowell VM, Verallo V, Graupe K, et al. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Dermato-Venereologica Supplementum. 1989;143:58–61.
- 13Ortonne JP, Arellano I, Berneburg M, et al. A global survey of the role of ultraviolet radiation and hormonal influences in the development of melasma. Journal of the European Academy of Dermatology and Venereology. 2009;23(11):1254–1262.
- 14American Academy of Dermatology. Melasma and post-inflammatory hyperpigmentation: patient education resources. Available at: aad.org
- 15DDC clinical governance: All pigmentation treatment content reviewed by named dermatologist. Medical registration numbers publicly verifiable.
Get your pigmentation typed before any treatment
The next step is not booking a laser. The next step is a clinical assessment that types your pigmentation, identifies triggers, confirms your skin is ready, and produces a layered plan calibrated for Indian skin.
- 30–45 minute dermatologist consultation
- Pigmentation typing, dermoscopy, Wood's lamp where indicated
- Standardised baseline photographs in fixed lighting
- Written multi-week plan with realistic expectations
- Sunscreen and trigger-control guidance
- Starting from ₹1,999 — final cost explained at consultation
Book your pigmentation consultation
By submitting this form, you agree to be contacted by our team. This form does not create a doctor-patient relationship.